Single rounded opacity less than or equal to 3 cm surrounded by aerated lung; managed by size, density, and risk via Fleischner criteria.
Also known as: SPN, pulmonary nodule, lung nodule, incidental nodule, Fleischner Society
Overview
A solitary pulmonary nodule is a discrete, well- or poorly defined rounded opacity less than or equal to 3 cm in diameter, completely surrounded by aerated lung parenchyma, without associated atelectasis, hilar enlargement, or pleural effusion. Lesions larger than 3 cm are termed masses and are presumed malignant until proven otherwise.
Epidemiology
Detected on roughly 1-2 of every 1,000 chest radiographs and far more frequently on chest CT (up to 50% of low-dose screening CTs identify at least one nodule). Malignancy rate ranges from less than 1% (small, low-risk) to over 50% (large, spiculated, high-risk smokers).
Try two board-style Solitary Pulmonary Nodule questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1PulmonaryMedium
A 50-year-old man with a 40 pack-year smoking history is found to have a solitary 7-mm solid pulmonary nodule on a CT scan obtained for an unrelated reason. He has no symptoms and no prior imaging available for comparison. There is no associated lymphadenopathy, and the remainder of the chest CT is normal. According to the Fleischner Society guidelines for incidental solid pulmonary nodules, which of the following is the most appropriate next step?
APET-CT of the chest within one month
BA single follow-up CT at 12 months
CFollow-up chest CT at 3 months
DCT at 6-12 months, then 18-24 months
ENo additional surveillance imaging
Reveal answer & full explanation
Correct answer: D — CT at 6-12 months, then 18-24 months
APET-CT of the chest within one month
BA single follow-up CT at 12 months
CFollow-up chest CT at 3 months
DCT at 6-12 months, then 18-24 months✓
ENo additional surveillance imaging
Why CT at 6-12 months, then 18-24 months is correct
For a solid, solitary nodule measuring 6-8 mm in a high-risk patient (heavy smoker), the Fleischner Society recommends an initial follow-up CT at 6-12 months and, if stable, a second CT at 18-24 months
Two stable time points are required to confirm the nodule is not growing, because a malignant nodule can have a long volume-doubling time
A 6-8 mm size with no suspicious features falls below the threshold for immediate tissue characterization
Why the others are wrong
No additional surveillance imaging — omitting follow-up applies only to nodules under 6 mm; a 7-mm nodule in a high-risk patient must be tracked (undertreatment, premature closure)
PET-CT of the chest within one month — PET-CT or tissue sampling is reserved for solid nodules larger than 8 mm or nodules that grow, and PET has poor sensitivity for sub-centimeter lesions (overtesting, anchoring on cancer fear)
A single follow-up CT at 12 months — one scan cannot establish two-year stability; the guideline requires a second interval scan, so a single follow-up risks missing slow growth (confused with the optional single 12-month CT Fleischner reserves for high-risk nodules under 6 mm)
Follow-up chest CT at 3 months — a short-interval CT at about 3 months is one of the options Fleischner offers for solid nodules larger than 8 mm; for a 6-8 mm nodule the first follow-up is at 6-12 months, and a single early scan cannot establish two-year stability (confusing the 6-8 mm and over-8 mm size thresholds)
Question 2PulmonaryMedium
A 55-year-old man with a 30-pack-year smoking history undergoes chest CT for evaluation of an unrelated complaint. The scan incidentally demonstrates a solitary 6-mm pure ground-glass nodule in the right upper lobe without a solid component. He is asymptomatic, his physical examination is unremarkable, and no prior chest imaging is available for comparison. According to Fleischner Society guidance, which of the following is the most appropriate next step in management?
ACT follow-up in 6-12 months
BNo further imaging follow-up
CPET scan and tissue biopsy
DCT follow-up in 3 months
ECT follow-up in 2 years
Reveal answer & full explanation
Correct answer: A — CT follow-up in 6-12 months
ACT follow-up in 6-12 months✓
BNo further imaging follow-up
CPET scan and tissue biopsy
DCT follow-up in 3 months
ECT follow-up in 2 years
Why CT follow-up in 6-12 months is correct
Per the Fleischner Society 2017 guidelines, a solitary pure ground-glass nodule ≥6 mm should be re-imaged with CT at 6-12 months to confirm it persists
Fleischner recommendations apply to incidentally detected nodules in adults 35 years and older, as in this patient; nodules found on lung cancer screening scans are managed by Lung-RADS instead
If the nodule persists and is unchanged, surveillance continues with CT every 2 years until 5 years, because pure ground-glass adenocarcinoma-spectrum lesions grow slowly
A solid component developing on follow-up would raise concern for invasive adenocarcinoma and prompt further workup
Why the others are wrong
CT follow-up in 3 months — a 3-month short-interval recheck belongs to suspicious solid or part-solid nodules; pure ground-glass lesions grow far too slowly for meaningful change at 3 months, so Fleischner sets the first recheck at 6-12 months (confused-with the solid-nodule schedule)
No further imaging follow-up — appropriate only for a pure ground-glass nodule <6 mm; at 6 mm this nodule meets the ≥6 mm threshold and warrants surveillance (confused-with the sub-6-mm rule)
PET scan and tissue biopsy — low yield for small pure ground-glass lesions (often falsely PET-negative) and premature before persistence or growth is documented (right-test-wrong-time)
CT follow-up in 2 years — every-2-year CT is the later surveillance cadence, used once a follow-up scan confirms the ground-glass nodule persists unchanged; the first recheck of a solitary pure ground-glass nodule ≥6 mm comes at 6-12 months to confirm persistence, since some such lesions are transient and resolve (right interval at the wrong stage)
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Solitary Pulmonary Nodule (Fleischner Evaluation) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Personal history of extrathoracic malignancy (especially head/neck, breast, colon, sarcoma, melanoma)
COPD and pulmonary fibrosis
Pathophysiology
Benign etiologies include infectious granulomas (tuberculosis, histoplasmosis, coccidioidomycosis), hamartomas, intrapulmonary lymph nodes, organizing pneumonia, and rheumatoid nodules. Malignant etiologies are most often primary lung adenocarcinoma, less commonly squamous cell, carcinoid, or solitary metastasis. Subsolid (ground-glass or part-solid) nodules carry the highest probability of representing adenocarcinoma spectrum lesions (atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma).
Clinical presentation
Symptoms
Most nodules are incidental and asymptomatic
Cough, hemoptysis, weight loss, or chest pain raise concern for malignancy or active infection
Constitutional symptoms (fever, night sweats) suggest infection or lymphoproliferative disease
Infectious granuloma — Endemic exposure (Ohio/Mississippi River valleys for histoplasmosis; southwest US for coccidioidomycosis); dense or popcorn calcification; stable for ≥2 years
Hamartoma — Smooth margins, fat density and popcorn calcification on CT pathognomonic, typically less than 2.5 cm
Primary lung adenocarcinoma — Spiculated margins, subsolid or part-solid density, growth on serial imaging, smoking history
Carcinoid tumor — Younger non-smokers, central or peripheral; well-defined, may be hypervascular; somatostatin receptor expression
Pulmonary metastasis — Known primary malignancy, multiple smooth nodules favored over solitary; history-driven
Rheumatoid or vasculitic nodule — Known autoimmune disease, may cavitate, often multiple; positive RF/anti-CCP or ANCA
Intrapulmonary lymph node — Small (<1 cm), oval, subpleural, below the carina; benign on serial imaging
Arteriovenous malformation — Feeding artery and draining vein on contrast CT; may be hereditary (HHT)
Diagnostic workup
Diagnostic criteria
Fleischner Society 2017 guidelines for incidental pulmonary nodules in adults ≥35 years (do NOT apply to lung cancer screening LDCT, oncology surveillance, or immunocompromised patients). Risk-stratify by patient risk and nodule size, density, and number.
Labs
CBC, CMP, LDH if malignancy suspected
Targeted infectious workup based on exposure: histoplasma urine antigen, coccidioides serology, QuantiFERON or PPD, sputum AFB if cavitary
Tumor markers are not used for diagnosis of SPN
Imaging
Compare with any prior chest imaging — stability for at least 2 years on solid nodules is strong evidence of benignity
Dedicated thin-section non-contrast chest CT to characterize size, density (solid, part-solid, ground-glass), margins, location, and calcification pattern
PET/CT for solid nodules ≥8 mm with intermediate pretest probability of malignancy
Biopsy options: CT-guided transthoracic needle biopsy (peripheral lesions), navigational or EBUS bronchoscopy (central or hilar lesions), surgical wedge for diagnostic and therapeutic resection
Treatment
First-line
Apply Fleischner 2017 algorithm by nodule type (solid vs subsolid), size, number, and risk (see table)
For low-risk solid nodules <6 mm: no routine follow-up
For high-risk solid nodules <6 mm: optional CT at 12 months
For solid nodules 6-8 mm: CT at 6-12 months, then consider CT at 18-24 months (low risk) or CT at 18-24 months (high risk)
For solid nodules >8 mm: CT at 3 months, PET/CT, tissue sampling, or referral to multidisciplinary team
For ground-glass nodules ≥6 mm: CT at 6-12 months then every 2 years for 5 years total
For part-solid nodules ≥6 mm: CT at 3-6 months; if persistent with solid component <6 mm, annual CT for 5 years; if solid component ≥6 mm, proceed to PET/biopsy/resection
High probability of malignancy (>65%)
Surgical candidate: proceed directly to surgical resection (a preoperative biopsy is not required). Nonsurgical candidate: nonsurgical biopsy (CT-guided for peripheral, bronchoscopic for central lesions) before stereotactic body radiation therapy
Staging with PET/CT; add brain MRI for clinical stage II or higher (consider in stage IB)
Intermediate probability (5-65%)
PET/CT to refine probability; FDG-avid lesions warrant biopsy or resection
PET-negative with low clinical probability (<30-40%): serial CT surveillance (about 3-6, 9-12, and 18-24 months); biopsy or resect if it grows. If pretest probability and PET are discordant (e.g., higher clinical probability with a negative PET), consider nonsurgical biopsy. Serial CT is also reasonable if comorbidities preclude intervention
Low probability (<5%)
Serial CT surveillance per Fleischner
Patient counseling and shared decision making about radiation and anxiety
Complications
Missed early lung cancer due to inadequate follow-up
Procedural complications from biopsy: pneumothorax (~15-25% for transthoracic needle biopsy), hemoptysis, infection
Radiation exposure from repeated CT surveillance
Patient anxiety and overdiagnosis of indolent ground-glass adenocarcinoma spectrum lesions
PANCE pearls
Fleischner criteria are for INCIDENTAL nodules — lung cancer screening LDCT findings follow Lung-RADS instead.
Benign calcification patterns: central, diffuse, laminated/concentric, and popcorn (hamartoma). Eccentric or stippled calcification does not exclude malignancy. Nodules with a benign calcification pattern or macroscopic fat (hamartoma) need no further imaging follow-up.
Doubling time of 20-400 days suggests malignancy; <20 days suggests infection or inflammation; >400 days suggests benignity.
Subsolid nodules require longer follow-up (up to 5 years) because adenocarcinoma in situ grows slowly.
Always compare with priors — stable ≥2 years on solid nodules essentially excludes malignancy.
Lung-RADS v2022 for screening LDCT (solid nodules): category 2 (baseline <6 mm or new <4 mm) gets annual LDCT; category 3 (baseline 6 to <8 mm or new 4 to <6 mm) gets LDCT in 6 months; category 4A (baseline 8 to <15 mm or new 6 to <8 mm) gets LDCT in 3 months, with PET/CT considered if the solid component is ≥8 mm; category 4B/4X gets diagnostic chest CT, PET/CT, and/or tissue sampling.
Estimate pretest probability with clinical judgment or a validated model (Mayo, Brock); older age, smoking, prior cancer, larger size, spiculation, and upper-lobe location raise it.
References
Fleischner Society 2017 — MacMahon H et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017;284:228-243
CHEST 2013 — Gould MK et al. Evaluation of Individuals with Pulmonary Nodules: When Is It Lung Cancer? ACCP Evidence-Based Clinical Practice Guidelines. CHEST 2013;143(5 Suppl):e93S-e120S
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.